Psyence Biomedical Ltd.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Psyence Biomedical Ltd. generated cash of -$2,945,367, which is less than the previous year. Cash used in financing activities reached the amount of $2,350,000 last year. Net change in cash is therefore -$601,092.
Cash Flow
| 2023 | -519.60K | 0 | 1.17M |
|---|---|---|---|
| 2024 | -2.94M | -5.72K | 2.35M |
PBM Cash Flow Statement (2022 – 2023)
| 2023 | 2022 | |
|---|---|---|
Cash at beginning of period | 1.33M | 648.28K |
Operating activities | ||
Net income | -51.15M | 8.01M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 240 | 0 |
Stock-based compensation expense | 317.88K | 221.28K |
| Deferred income tax benefit | 317.88K | 221.28K |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 107.62K | 0 |
Inventories | 0 | 0 |
Accounts payable | 0 | 0 |
Cash generated by operating activities | -2.94M | -519.60K |
Investing activities | ||
Purchases Of Investments | 0 | 0 |
Investments In Property Plant And Equipment | -5.72K | 0 |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | -5.72K | 0 |
Financing activities | ||
Common Stock Issued | 0 | 0 |
Payments for dividends | 0 | 0 |
Repurchases of common stock | 0 | 0 |
Repayments of term debt | 2.35M | 0 |
Cash used in financing activities | 2.35M | 1.17M |
Net Change In Cash | -601.09K | -519.60K |
Cash at end of period | 733.18K | 128.67K |